74 results
10-K
2023 FY
EX-10.12
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
become invalid. (vi) The Parties’ assessment of currently Applicable Law is that [***]. (c) Information and Assistance. Each Party shall, [***] following
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
were MRD negative at last assessment and median duration of response was not reached.
Patients continue to be enrolled into the Phase 1 ALLCAR19 … remission were MRD negative at last assessment and median duration of response was not reached.
Table of contents
Development Strategy for Adult ALL
8-K/A
EX-99.1
AUTL
Autolus Therapeutics plc
15 Mar 24
Results of Operations and Financial Condition
4:21pm
for assessment. So that different phase and different views that are taken in terms of analyzing data and it really depends on the agency. But that's
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
14 Mar 24
Results of Operations and Financial Condition
12:32pm
-protocol anti-cancer therapies including SCT with disease assessment by IRRC (data cut-off date: September 13, 2023); BM, bone marrow; CI, confidence … -related per investigator assessment: neutropenic sepsis (n = 1); acute respiratory distress syndrome and ICANS (n = 1) BM, bone marrow; CRS, cytokine
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
13 Feb 24
Regulation FD Disclosure
4:06pm
*Censoring new non-protocol anti-cancer therapies including SCT with disease assessment by IRRC (data cut-off date: September 13, 2023); Median EFS: ITT … 30 40 50 60 70 80 90 100 Probability (%) *Censoring new non-protocol anti-cancer therapies including SCT with disease assessment by IRRC (data cut-off
8-K
EX-10.1
kshr1h
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
S-3ASR
EX-4.7
kj98 tg4e0
7 Feb 24
Automatic shelf registration
10:00pm
8-K
EX-99.2
3ggt67ghfs1ay9xhg6
11 Dec 23
Regulation FD Disclosure
8:31am
8-K
EX-99.1
2eg2t i3e
11 Dec 23
Regulation FD Disclosure
8:31am
10-Q
wgk26nglpg
9 Nov 23
Quarterly report
4:18pm
6-K
EX-99.2
rl185q13ieylrgefv1m
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.2
gwzfsvjk
3 Aug 23
Index to Condensed Consolidated Financial Statements
4:32pm
6-K
EX-99.2
1482xet ogt9x3s7auo
4 May 23
Index to Condensed Consolidated Financial Statements
4:04pm
424B5
gqkxq9
9 Dec 22
Prospectus supplement for primary offering
5:40pm
424B5
w1xxb4fv mzapen0z
8 Dec 22
Prospectus supplement for primary offering
4:10pm
6-K/A
EX-99.2
cvb8dbii
21 Nov 22
Current report (foreign) (amended)
4:03pm
6-K
EX-99.2
q9gijsb21skqipbrnm
3 Nov 22
Index to Condensed Consolidated Financial Statements
10:31am
6-K
EX-99.2
ynqjxaxel6ni7x9up zz
4 Aug 22
Index to Condensed Consolidated Financial Statements
4:06pm
6-K
EX-1
1bqy9v8j6cmoe3iz
1 Jul 22
Current report (foreign)
5:15pm